0VY Stock Overview A clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for I-Mab Historical stock prices Current Share Price US$0.88 52 Week High US$2.14 52 Week Low US$0.85 Beta 1.04 1 Month Change -2.76% 3 Month Change -6.38% 1 Year Change -37.14% 3 Year Change -97.83% 5 Year Change n/a Change since IPO -92.41%
Recent News & Updates
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023) Nov 17
I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer Nov 06
I-Mab to Report Q3, 2024 Results on Nov 14, 2024 Oct 31
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 Sep 17
First half 2024 earnings released: US$0.19 loss per share (vs US$1.32 loss in 1H 2023) Aug 29
I-Mab to Report First Half, 2024 Results on Aug 28, 2024 Aug 14 See more updates
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023) Nov 17
I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer Nov 06
I-Mab to Report Q3, 2024 Results on Nov 14, 2024 Oct 31
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 Sep 17
First half 2024 earnings released: US$0.19 loss per share (vs US$1.32 loss in 1H 2023) Aug 29
I-Mab to Report First Half, 2024 Results on Aug 28, 2024 Aug 14
New minor risk - Market cap size Aug 06
Insufficient new directors Jul 17 I-Mab Announces Board and Committee Changes
I-Mab Appoints Phillip Dennis as Chief Medical Officer Jun 08 I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB). Apr 03
Full year 2023 earnings released: CN¥16.53 loss per share (vs CN¥29.23 loss in FY 2022) Mar 18
New minor risk - Financial data availability Mar 15 I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million. Feb 08
I-Mab Announces Board Changes , Effective February 10, 2024
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN) Nov 04
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023 Oct 17
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503 Oct 11
New major risk - Share price stability Oct 05
I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares. Aug 18
I-Mab to Report First Half, 2023 Results on Aug 17, 2023 Aug 09 I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors
TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma Jun 16
First half 2022 earnings released: CN¥12.75 loss per share (vs CN¥14.67 loss in 1H 2021) Nov 16
Less than half of directors are independent Nov 16
I-Mab Announces Management Changes Oct 02
I-Mab Announces Executive Changes Oct 01
I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD) Sep 19
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome Sep 14
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 Sep 11 I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.
I-Mab to Report First Half, 2022 Results on Aug 30, 2022 Aug 20
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China Jul 23
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa) Jun 15
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency Jun 01
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab May 27
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab May 20
I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest Apr 21
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors Jan 19
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors Jan 13
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors Dec 28
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China Dec 16
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma At ASH 2021 Dec 15
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease Dec 09
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors Dec 05
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors Oct 01
Investor sentiment deteriorated over the past week Aug 21
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of Its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe Covid-19 Aug 12
Investor sentiment deteriorated over the past week Jul 28
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio Jul 03
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus Jun 26
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 May 21
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome May 19
Investor sentiment improved over the past week May 18
Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019) May 01
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis Apr 27
Investor sentiment improved over the past week Apr 20
Full year 2020 earnings released: EPS CN¥8.07 (vs CN¥463 loss in FY 2019) Apr 01 I-Mab to Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab At 2021 American Association for Cancer Research Annual Meeting
I-Mab to Report Fiscal Year 2020 Results on Mar 29, 2021 Mar 04
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency Feb 26
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors Feb 11
I-Mab has completed a Follow-on Equity Offering in the amount of $177.3333 million. Feb 10
I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S Feb 06
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China Feb 05
New 90-day high: €51.00 Feb 02
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer Jan 26
New 90-day high: €37.60 Jan 05
Revenue in line with expectations Dec 06
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China Dec 06
Revenue in line with expectations Dec 03
I-Mab Announces Appointments to its Scientific Advisory Board Dec 02
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 Nov 12
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting Nov 10
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Oct 29
I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Oct 16
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency Oct 04
New 90-day high: €39.80 Oct 01
I-Mab announced that it expects to receive $418.002417 million in funding from a group of investors Sep 23
I-Mab Announces That the Center for Drug Evaluation of the China National Medical Products Administration Has Cleared the Investigational New Drug Application for Lemzoparlimab Sep 22
New 90-day high - €30.40 Sep 02
First half earnings released Sep 01 Shareholder Returns 0VY DE Biotechs DE Market 7D -5.9% -2.6% -2.0% 1Y -37.1% -13.2% 6.8%
See full shareholder returns
Return vs Market: 0VY underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 0VY's price volatile compared to industry and market? 0VY volatility 0VY Average Weekly Movement 12.2% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0VY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0VY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy.
Show more I-Mab Fundamentals Summary How do I-Mab's earnings and revenue compare to its market cap? 0VY fundamental statistics Market cap €72.28m Earnings (TTM ) -€194.58m Revenue (TTM ) €3.18m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0VY income statement (TTM ) Revenue US$3.31m Cost of Revenue US$0 Gross Profit US$3.31m Other Expenses US$205.81m Earnings -US$202.50m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.48 Gross Margin 100.00% Net Profit Margin -6,110.39% Debt/Equity Ratio 0%
How did 0VY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 16:03 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources I-Mab is covered by 19 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bo Li BofA Global Research Louise Chen Cantor Fitzgerald & Co. Ziyu He China International Capital Corporation Limited
Show 16 more analysts 
